Burning Rock Biotech (BNR) Receivables - Net (2019 - 2026)

Burning Rock Biotech (BNR) has reported Receivables - Net for 8 consecutive years, with $23.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Net rose 8.52% year-over-year to $23.8 million; the TTM figure through Mar 2026 stood at $23.8 million (up 8.52% YoY), while the FY2025 annual figure was $24.3 million, down 10.53% from the prior year.
• Receivables - Net came in at $23.8 million for Q1 2026 at Burning Rock Biotech, roughly flat from $23.9 million in the prior quarter.
• The five-year high for Receivables - Net was $26.5 million in Q2 2025, with the low at $14.4 million in Q3 2022.
• Average Receivables - Net over 5 years is $20.2 million, with a median of $19.8 million recorded in 2023.
• The largest YoY upside for Receivables - Net was 40.6% in 2022 against a maximum downside of 0.14% in 2022.
• Year by year, Receivables - Net stood at $15.5 million in 2022, then grew by 13.97% to $17.6 million in 2023, then gained by 20.11% to $21.2 million in 2024, then climbed by 13.0% to $23.9 million in 2025, then declined by 0.28% to $23.8 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $23.8 million, $23.9 million, and $25.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.